EBMT Annual report 2023



ScienceEducationPatient Care & Advocacy Our SocietyOur Mission, Vision & ValuesEBMT Membership 2023Organisational Structure 2023Financial Highlights 2023EBMT Partners

Breadcrumb

1. <u>Home</u>

Entity Print



Zinaida Perić TCWP Chair Croatia

Major achievements

During 2023 the TCWP finalised several important projects including the **new guidelines** on prevention and management of GVHD as well as joint ERS/EBMT Task force guidelines on pulmonary GVHD which are both in the process of publications. Several other important **studies** were also finalised in the form of publications, including the first real-life experience with cytopenias and organ complications after CAR-T therapies as well as the first AI study conducted in the TCWP on the mortality and NRM after allogeneic HSCT.

Furthermore, the TCWP followed the same successful format of the previous year and conducted a successful **educational meeting** in September in Copenhagen in a format of patient case discussion and sharing practical skills. Patient advocates, nurses and physicians all participated, significantly improving the audience engagement in the activities and resulting in a very positive feedback.

Finally, significant work was also done in the **harmonisation of definitions** for the new EBMT Registry to improve the quality and speed of TCWP studies in the future.

Principal research studies

Daratumumab for PRCA after alloSCT Study type **Retrospective Studies** Diseases Complications: non-infectious Group Transplant Complications Working Party (TCWP) Type of treatment Principal investigator Nico Gagelmann Immune Checkpoint Inhibitors for solid tumors after allogeneic stem cell transplantation Study type **Retrospective Studies** Diseases All diseases Group Transplant Complications Working Party (TCWP) Type of treatment Allogeneic Principal investigator

Jan Brijs Outcomes of Allogeneic Hematopoietic Cell Transplantation from $\leq 8/10$ -HLA matched unrelated donor Study type **Retrospective Studies** Diseases All diseases Group Transplant Complications Working Party (TCWP) Type of treatment Allogeneic Principal investigator Ivan Moiseev Outcomes and risk factors for survival of lung transplantation after allogeneic HSCT Study type **Retrospective Studies** Diseases Group Transplant Complications Working Party (TCWP) Type of treatment Allogeneic Principal investigator Juan Montoro Gomez; Saskia Bos How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time Study type **Retrospective Studies** Diseases All diseases Group Transplant Complications Working Party (TCWP) Type of treatment Allogeneic Principal investigator

Olaf Penack

Evaluating the Impact of ABO Compatibility on Allogeneic Stem Cell Transplantation Outcomes <u>Study type</u> <u>Retrospective Studies</u> <u>Diseases</u> <u>All diseases</u> <u>Group</u> <u>Transplant Complications Working Party (TCWP)</u> <u>Type of treatment</u> <u>Allogeneic</u> <u>Principal investigator</u> Mustafa Güven

Key publications

<u>2023</u>

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party Group Cellular Therapy & Immunobiology Working Party (CTIWP) Infectious Diseases Working Party (IDWP) Transplant Complications Working Party (TCWP) 1st listed author **Olaf Penack** lournal | Immunother Cancer. 2023 Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party Group Transplant Complications Working Party (TCWP) Lymphoma Working Party (LWP) 1st listed author **Olaf Penack** Journal Front Immunol. 2023 ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party

Group Transplant Complications Working Party (TCWP) 1st listed author **Olaf Penack** Journal Front Immunol. 2023 The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party Group Transplant Complications Working Party (TCWP) 1st listed author Lars Klingen Gjærde Journal Bone Marrow Transplant. 2023 Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study Group Transplant Complications Working Party (TCWP) 1st listed author A Mussetti Journal Bone Marrow Transplant. 2023 Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant **Complications Working Party study** Group Transplant Complications Working Party (TCWP) 1st listed author Tapani Ruutu Journal Bone Marrow Transplant. 2023 Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications

Working Party of the EBMT Group Transplant Complications Working Party (TCWP) 1st listed author Lars Klingen Gjærde Journal






2021 2022 2023

Oral presentations	2	6	1
Poster presentations	2	5	9
Educational events	1	1	1

Major educational events



<u>Event</u>

49th Annual Meeting of the EBMT



Event

TCWP Educational Meeting 2023 on How to survive stem cell transplantation and CAR T-cell therapy - guide for physicians and nurses

Sep 14, 2023 - Sep 16, 2023 / Copenhagen, Denmark Discover more VISIT THE TCWP WEBPAGE